SCHEMBL22720585

SCHEMBL22720585

CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CC1=C=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.43
ADORA1 P30542 1/20 0.41
GPR119 Q8TDV5 5/20 0.39
MAPT P10636 3/20 0.39
DPP4 P27487 1/20 0.39
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ESR2 Q92731 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19073726 0.84 MEN1 (0.45) MEN1ALDH1A1KMT2ATSHRADORA1
SCHEMBL652243 0.84 MEN1 (0.45) MEN1ALDH1A1KMT2ATSHRADORA1
SCHEMBL29579744 0.82 MEN1 (0.47) MEN1ALDH1A1KMT2ATSHRADORA1
SCHEMBL29603736 0.81 MAPT (0.36) MEN1ALDH1A1KMT2ATSHRADORA1
SCHEMBL183757 0.78 MEN1 (0.44) MEN1ALDH1A1KMT2ATSHRADORA1
SCHEMBL20015491 0.78 MEN1 (0.44) MEN1ALDH1A1KMT2ATSHRADORA1
SCHEMBL22720287 0.77 FPR2 (0.39) MEN1ALDH1A1KMT2ATSHRADORA1
SCHEMBL183517 0.77 ALDH1A1 (0.44) MEN1ALDH1A1KMT2ATSHRADORA1
SCHEMBL4167125 0.76 HPGD (0.47) MEN1ALDH1A1KMT2ATSHRGPR119
SCHEMBL1622326 0.76 MAPT (0.43) MEN1ALDH1A1KMT2ATSHRGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497396-B2 Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-12-16 US disclosed
US-20220213100-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2022-07-07 US disclosed
EP-3978490-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2022-04-06 EP disclosed
CN-113423703-A Nitrogen-containing heterocyclic derivative regulator, and preparation method and application thereof 上海翰森生物医药科技有限公司 2021-09-21 CN disclosed
WO-2020239077-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2020-12-03 WO disclosed
CN-103936663-A A preparation method of 1-R1-3, 3-difluoro (or 3-fluoro)-4-R2-4-aminomethylpiperidine and its derivatives SHANGHAI AQBIOPHARMA CO LTD 2014-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213100-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF KRAS, NRAS, GNAQ MEN1 136/4885ALDH1A1 2591/4885KMT2A 2560/4885
US-12497396-B2 Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers KRAS, NRAS, GNAQ MEN1 85/4885ALDH1A1 2233/4885KMT2A 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.